Incyte Corporation

INCY

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase3 readout (Baricitinib): Apr 2022. Short interest: 9.8% of float.

BiotechnologyCEO: William J. MeuryIPO: 1993Website ↗

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Catalysts

Phase 2PositiveQ2 2010RuxolitinibMyeloproliferative Neoplasm (MPN)NCT00726232

Primary: Percentage of Polycythemia Vera Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR) (Assessed after 2 cycles (56 days) of treatment on Day 1 of Cycle 3)Enrollment:73/73Sites: 4RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2018NivolumabLung CancerNCT03348904

Primary: Overall Survival (OS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B) (Approximately 38 months)Enrollment:2/2Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2019PembrolizumabLung CancerNCT03322540

Primary: Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus Placebo (Up to approximately 6 months)Enrollment:154/154Sites: 101RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2019MEDI4736Solid Tumors, Head and Neck Cancer, Lung CancerNCT02318277

Primary: Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE) (Duration of study treatment and up to 90 days after the last dose [approximately 3 years])Enrollment:176/176Sites: 13NA, TREATMENT

Phase 3Apr 24, 2022BaricitinibAtopic DermatitisNCT03952559

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement (Week 16)Enrollment:516/516Sites: 78RANDOMIZED, DOUBLE, TREATMENT

Phase 2Sep 8, 2022INCMGA00012GlioblastomaNCT04225039

Primary: Objective Radiographic Response (ORR) (26 months)Enrollment:39/39Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Sep 19, 2022RuxolitinibChronic Myelomonocytic Leukemia, LeukemiaNCT03722407

Primary: Overall Response (At week 16)Enrollment:29/29Sites: 5NA, TREATMENT

Phase 2PositiveQ4 2022Ruxolitinib creamVitiligoNCT04896385

Primary: Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24 (Baseline; Week 4, Week 12, and Week 24)Enrollment:60/60Sites: 13RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ4 2022ruxolitinib creamAtopic DermatitisNCT04839380

Primary: Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application) (Baseline; Day 2)Enrollment:49/49Sites: 2NA, TREATMENT

Phase 2Dec 2, 2022ruxolitinibOther CancerNCT03674047

Primary: absolute FEV1 increase (3 Months)Enrollment:50/50Sites: 7NON_RANDOMIZED, TREATMENT

Phase 2Dec 28, 2022BusulfanPrimary Myelofibrosis, Secondary MyelofibrosisNCT02251821

Primary: 2-year Overall Survival (OS) in Patients With Myelofibrosis (MF) Who Receive Treatment With a JAK Inhibitor Followed by an Allogeneic Transplant (2 years)Enrollment:61/61Sites: 1NA, TREATMENT

Phase 2Dec 31, 2022RuxolitinibInflammatory Breast Cancer (IBC)NCT02876302

Primary: Biologic Response To 7-Day Run-In Window Phase Treatment of Ruxolitinib Alone or Ruxolitinib Plus Paclitaxel (7 days)Enrollment:23/23Sites: 4RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2023INCB054707Prurigo NodularisNCT05061693

Phase 3PositiveQ4 2023RetifanlimabMetastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung CancerNCT04205812

Primary: Overall Survival (up to 39.1 months)Enrollment:583/583Sites: 140RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2024tafasitamabFollicular Lymphoma, Marginal Zone LymphomaNCT04680052

Phase 2Q3 2024TafasitamabDiffuse Large B Cell LymphomaNCT05222555

Phase 2Sep 9, 2024EpacadostatSarcomaNCT03414229

Phase 2Q1 2025RetifanlimabHead and Neck CancerNCT05287113

Phase 2Q2 2025INCB000928Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera MyelofibrosisNCT04455841

Phase 2May 1, 2025CapecitabineGastric Adenocarcinoma, Esophageal AdenocarcinomaNCT05177133

Phase 2Jun 30, 2025PelareorepAnatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaNCT04445844

Phase 2Q3 2025tafasitamabNon Hodgkins Lymphoma, Diffuse Large B-cell LymphomaNCT04661007

Phase 3Q3 2025INCA034176Chronic Graft-versus-host-diseaseNCT06263478

Phase 2Sep 25, 2025RuxolitinibChronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic PhaseNCT03610971

Phase 2Sep 30, 2025TafasitamabCNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System LymphomaNCT05351593

Phase 2Nov 7, 2025RuxolitinibHemophagocytic LymphohistiocytosisNCT04551131

Phase 2Q4 2025Ponatinib 15 MGChronic Myeloid Leukemia, Chronic PhaseNCT04160546

Phase 2Q1 2026RuxolitinibDuctal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal HyperplasiaNCT02928978

Phase 3Q1 2026PovorcitinibNon Segmental VitiligoNCT06113445

Phase 3Q1 2026PovorcitinibNon Segmental VitiligoNCT06113471

Phase 2Q1 2026Ruxolitinib Topical CreamExanthema, Lichenoid Skin Rashes Under Anti-PD1 Tumor TherapyNCT06399029

Phase 2Q1 2026RuxolitinibHodgkin LymphomaNCT03681561

Phase 2Q1 2026DoxorubicinResectable SarcomaNCT04968106

Phase 3Q2 2026TafasitamabLarge B-Cell Lymphoma, Diffuse Large B-Cell LymphomaNCT05429268

Phase 2Q2 2026retifanlimabEndometrial CancerNCT04463771

Phase 2May 1, 2026CyclophosphamideB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeNCT05453500

Phase 2Q2 2026INCB177054Solid Tumors, Advanced Solid Tumors, Metastatic Solid TumorsNCT06873789

Phase 2Q2 2026AxatilimabHodgkin LymphomaNCT05723055

Phase 2Q2 2026povorcitinibModerate to Severe AsthmaNCT05851443

Phase 2Jun 20, 2026ItacitinibDiffuse Large B Cell LymphomaNCT05757219

Phase 2Q2 2026itacitinibMyelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host DiseaseNCT04640025

Phase 2Q2 2026INCMGA00012Well-differentiated/Dedifferentiated LiposarcomaNCT04438824

Phase 2Q3 2026INCA034176Chronic Graft-versus-host-diseaseNCT06843408

Primary: Number of participants with Treatment-emergent Adverse Events (TEAEs) (Up to 2 years and 30 days)Enrollment:Target 30Sites: 9NA, TREATMENT

Phase 3Q3 2026RuxolitinibAtopic DermatitisNCT06832618

Phase 2Q3 2026INCB099280Advanced Solid TumorNCT05879822

Phase 2Q3 2026PemigatinibIntrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene MutationNCT06728410

Phase 3Q3 2026Ruxolitinib CreamNon Segmental VitiligoNCT06548360

Phase 3Q3 2026TafasitamabDiffuse Large B-cell LymphomaNCT04824092

Primary: PFS-INV (Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months))Enrollment:899/899Sites: 307RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026INCB099280Cutaneous Squamous Cell CarcinomaNCT05888844

Phase 2Sep 29, 2026RetifanlimabSoft Tissue Sarcoma, Sarcoma, Soft Tissue, SarcomaNCT04577014

Phase 3Sep 30, 2026PrednisoneAcute Lymphoblastic Leukemia, Acute Lymphoblastic LymphomaNCT03117751

Phase 3Q4 2026Ruxolitinib CreamHidradenitis SuppurativaNCT06959225

Phase 3Q4 2026Ruxolitinib CreamHidradenitis SuppurativaNCT06958211

Phase 3Q4 2026PovorcitinibPrurigo NodularisNCT06516965

Phase 3Q4 2026PovorcitinibPrurigo NodularisNCT06516952

Phase 2NegativeQ4 2026Ruxolitinib 1.5% CreamHidradenitis SuppurativaNCT04414514

Phase 2Dec 1, 2026PembrolizumabTNBC - Triple-Negative Breast Cancer, Breast CancerNCT05491226

Primary: Pathological complete response (pCR) rate. (From treatment start date until the time of curative-intent treatment, approximately 7 weeks.)Enrollment:Target 35Sites: 1NA, TREATMENT

Phase 3Q4 2026PovorcitinibHidradenitis Suppurativa (HS)NCT06212999

Phase 2Dec 31, 2026LenalidomideGrade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsNCT05890352

Phase 2Dec 31, 2026RuxolitinibT-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-CellNCT07356245

Phase 2Dec 31, 2026PemigatinibAdvanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8NCT06906562

Phase 2Jan 1, 2027RuxolitinibSplenomegaly, MyelofibrosisNCT06345495

Phase 2Q1 2027PemigatinibRelapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaNCT06300528

Phase 2Q1 2027TafasitamabLarge B-cell LymphomaNCT06760156

Phase 2Jan 31, 2027RetifanlimabUnresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell CarcinomaNCT06056895

Phase 2Feb 6, 2027topical ruxolitinib 1.5% creamNon-sclerotic Cutaneous Chronic Graft-versus-host DiseaseNCT03954236

Phase 2Q1 2027TafasitamabNon-Hodgkin LymphomaNCT05583071

Phase 2Q1 2027RuxolitinibMyelofibrosisNCT03069326

Phase 2Apr 1, 2027AxatilimabAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid NeoplasmNCT06320405

Phase 2Apr 1, 2027BusulfanHematologic and Lymphocytic DisorderNCT04859946

Phase 2Q2 2027INCB123667Ovarian CancerNCT07023627

Phase 3Q2 2027Ruxolitinib CreamNon Segmental VitiligoNCT06804811

Phase 2Jun 1, 2027RuxolitinibLeukemia, Myelodysplasia, Chronic Myelomonocytic LeukemiaNCT07249346

Phase 2Jun 1, 2027RetifanlimabGlioma, IDH Mutation, AstrocytomaNCT05345002

Phase 2Q2 2027AxatilimabChronic Graft-versus-host-diseaseNCT06388564

Phase 2Jun 1, 2027RuxolitinibAcute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse EffectsNCT06936566

Phase 2Jun 30, 2027PemigatinibSolid Tumor, MiscellaneousNCT06653777

Phase 2Jul 15, 2027EpacadostatRectal CancerNCT03516708

Phase 2Q3 2027INCB000928Fibrodysplasia Ossificans Progressiva (FOP)NCT05090891

Phase 2Q3 2027RuxolitinibEssential Thrombocythemia, Polycythemia VeraNCT04644211

Phase 2Q3 2027TafasitamabHematologic MalignanciesNCT06465433

Phase 2Q3 2027ASTX727MDS/MPNNCT04061421

Phase 2Q3 2027INCA000585Immune ThrombocytopeniaNCT07104565

Phase 3Q3 2027INCA034176Chronic Graft-versus-host-diseaseNCT06585774

Phase 2Q3 2027PanitumumabCancer, Tumors, NeoplasmNCT02925234

Phase 2Q3 2027ParsaclisibB-Cell MalignanciesNCT04509700

Phase 2Q3 2027RuxolitinibPancreatic Cancer, Colorectal Cancer (CRC), Breast CancerNCT02955940

Phase 2Oct 31, 2027AxatilimabAtypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative NeoplasmNCT06523556

Phase 2Q4 2027RuxolitinibNon Small Cell Lung Carcinoma, Renal Cell CarcinomaNCT07219576

Phase 2Dec 31, 2027CyclosporineAplastic AnemiaNCT06752694

Phase 2Dec 31, 2027RuxolitinibHemophagocytic LymphohistiocytosesNCT06160791

Phase 2Jan 30, 2028EnzalutamideCastration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8NCT06616155

Phase 2Q1 2028UlixertinibMyelofibrosisNCT06773195

Phase 2Q1 2028RuxolitinibNon-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ RelapsedNCT07283822

Phase 2Q1 2028PonatinibAcute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid LeukemiaNCT03934372

Phase 2Feb 22, 2028PemigatinibAdvanced Cholangiocarcinoma, FGFR2 FusionNCT06439485

Phase 3Q1 2028povorcitinibHidradenitis Suppurativa (HS)NCT06855498

Phase 2Q1 2028PovorcitinibHidradenitis Suppurativa (HS)NCT07213973

Phase 2May 1, 2028ZanubrutinibMantle Cell LymphomaNCT06029309

Phase 3Q2 2028INCA034176Chronic Graft-versus-host-diseaseNCT06821542

Phase 2Q2 2028Conditioning Regimen AAML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)NCT06859424

Phase 2Aug 10, 2028AxatilimabChronic Graft Versus Host DiseaseNCT07011810

Phase 2Q3 2028EpcoritamabLymphomaNCT07030699

Phase 3Q3 2028INCB161734Solid TumorsNCT07522073

Phase 2Oct 1, 2028PemigatinibSDH Gene Mutation, Gastrointestinal Stromal TumorNCT07434843

Primary: Objective radiographic response rate (From first dose of pemigatinib until the date of objective response per RECIST 1.1 through study completion, an average of 1 year)Enrollment:Target 24Sites: 1NA, TREATMENT

Phase 3Q4 2028INCB123667Ovarian CancerNCT07214779

Phase 2Nov 19, 2028RuxolitinibSickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell TransplantNCT07252050

Phase 3Q4 2028INCA33890CRC (Colorectal Cancer)NCT07284849

Phase 2Dec 30, 2028RuxolitinibBCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated CellsNCT03801434

Phase 2Q4 2028RuxolitinibChronic Graft-versus-host Disease (c GVHD)NCT06660355

Phase 2Dec 31, 2028RuxolitinibCastleman's Disease (CD), Idiopathic Multicentric Castleman's DiseaseNCT07085039

Phase 2Q1 2029CyclophosphamideHematologic MalignanciesNCT07359859

Phase 2Q1 2029INCA034176Chronic Graft-versus-host-diseaseNCT07124078

Phase 2Q1 2029ChemotherapyAnal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the AnusNCT07425054

Phase 3Q2 2029INCA033989Essential ThrombocythemiaNCT07623200

Phase 2Jul 8, 2029TafasitamabFollicular Lymphoma, Marginal Zone LymphomaNCT06792825

Phase 2May 5, 2030AxatilimabChronic Graft Versus Host Disease, c GVHDNCT06663722

Phase 3Q3 2030parsaclisibMantle Cell LymphomaNCT04849715

Phase 2Sep 1, 2030RuxolitinibMyelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary MyelofibrosisNCT07228624

Phase 2Q4 2030RuxolitinibGlioblastoma, Brain Cancer, Glioblastoma MultiformeNCT06991101

Phase 3Q1 2031Tacrolimus (Tac)Graft-versus-host Disease (GVHD)NCT06615050

Phase 2Jul 31, 2031Axatilimab (SNDX-6352)Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)NCT07128381

Phase 2Q4 2031EpcoritamabLarge B Cell LymphomaNCT07126236

Phase 2Q4 2032PembrolizumabTNBC - Triple-Negative Breast Cancer, Breast CancerNCT07015853

Recent News & Research

bioRxiv

Population genetics meets precision-cut kidney slices: Nephrotoxicity modelled ex vivo in the founder strains of the BXD mouse consortium

# Investment Summary: Limited Direct Relevance to Incyte This preclinical toxicology study using mouse kidney tissue models has no apparent connection to Incyte's pipeline or marketed products (JAK inhibitors, IDO1 inhibitors, other oncology/inflammatory assets). The research addresses general nephrotoxicity screening methodology rather than a specific drug candidate or therapeutic area where Incyte operates. **Investor takeaway:** This publication does not materially impact Incyte's clinical development programs, regulatory pathway, or commercial prospects. Monitor only if Incyte specifically licenses or applies this ex vivo model to evaluate safety profiles of its own compounds in development.

Jun 21, 2026

bioRxiv

Mutation count and mutation profile analyses of single-nucleotide variants in single human colon crypts

# Investment Summary: Not Material to INCY This basic research article on somatic mutation accumulation in normal colon tissue has no direct relevance to Incyte's pipeline or commercial products. The study examines mutation profiles in healthy colon crypts rather than disease mechanisms or therapeutic targets that Incyte develops drugs against (JAK inhibitors, oncology, inflammatory conditions). **Why this matters for investors:** This is foundational genomics work with no clear application to Incyte's marketed drugs (Jakafi, Opzelura) or clinical-stage candidates. Monitor instead Incyte's clinical readouts, regulatory decisions, and pipeline advancement in their core therapeutic areas.

Jun 14, 2026

bioRxiv

ATR kinase inhibitors induce mitochondrial fission in CD8+ T cells and impair immune memory in vivo

# Investment Summary: ATR Inhibitor Research **Clinical/Commercial Implication:** This study demonstrates that ATR kinase inhibitors—a class Incyte is developing (e.g., M6620)—impair CD8+ T cell memory formation by inducing mitochondrial dysfunction, potentially limiting their efficacy as cancer immunotherapies and suggesting a previously uncharacterized mechanism of immune toxicity that could constrain clinical applications or require combination strategies to mitigate. **Why It Matters:** For investors, this represents a potential development risk if Incyte's ATR program relies on CD8+ T cell-dependent anti-tumor immunity; the finding could necessitate additional clinical monitoring for immune memory deficits, restrict patient populations, or require redesign of dosing/combinations, any of which could impact peak sales projections or time-to-market.

May 26, 2026

bioRxiv

Post-daunorubicin treatment effects on cardiovascular function in the Ts65Dn mouse model of Down syndrome

# Summary This study examines cardiotoxicity mechanisms in a Down syndrome mouse model following daunorubicin treatment, a chemotherapy agent used in pediatric leukemia protocols. The research has limited direct relevance to Incyte's current pipeline, as the company does not have active development programs in daunorubicin or Down syndrome-related cardiotoxicity, and the work remains in preclinical mouse models without clinical data translation. **Investment relevance**: This basic research does not materially impact INCY's commercial outlook or ongoing clinical programs in oncology, hematology, or other therapeutic areas where the company is focused.

May 26, 2026

bioRxiv

An oncolytic adenovirus armed with anticancer prodrug-activating enzyme offers enhanced tumor killing and antitumor immunity.

# Research Summary: Oncolytic Adenovirus with Prodrug-Activating Enzyme **Clinical/Commercial Relevance to INCY:** This preprint describes an engineered oncolytic adenovirus platform that combines direct tumor lysis with localized prodrug activation—a mechanism conceptually aligned with Incyte's expertise in targeted cancer immunotherapy and its pipeline of prodrug-based candidates. The approach demonstrates dual efficacy through tumor cell killing and immune activation, which could address efficacy plateaus in immuno-oncology if validated in human trials and could represent a potential partnering or acquisition target. However, as a bioRxiv preprint without peer review or clinical data, the commercial timeline and competitive positioning versus Incyte's existing assets (including checkpoint inhibitors and engineered cell therapies) remain uncertain and would require Phase 1 data to assess strategic value.

May 26, 2026

Incyte Corporation

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research